Genetic GHSR deficiency and LEAP2 treatment enhance the glucose-lowering effects of liraglutide in male mice in a metabolic state-dependent manner.
Inhibition of GHSR may enhance the glucose-lowering effects of liraglutide in male mice, but further research is needed to determine the relevance of these findings in humans.
Where it sits
this study against the rest of the liraglutide corpusSummary and findings
This study investigated the effects of liraglutide on glycemia in male mice with genetic GHSR deficiency and pharmacological GHSR blockade. It was found that liraglutide reduced glycemia more effectively in GHSR-null male mice than in control mice under certain conditions. The study also explored the cellular mechanisms involved using murine islets and human pancreatic tissue.
Abstract
<h4>Aims</h4>Liraglutide is a glucagon-like peptide-1 receptor (GLP-1R) agonist that lowers glycemia and is used to treat type 2 diabetes (T2D) and obesity. Activation of the growth hormone secretagogue receptor (GHSR) increases glycemia. We aimed to determine whether GHSR inhibition enhances the glucose-lowering effects of liraglutide.<h4>Materials and methods</h4>We investigated the acute glucose-lowering effects of liraglutide in mice with genetic GHSR deletion or pharmacological GHSR blockade under fed, fasting, and postprandial conditions. We also examined the potential cellular basis of this interaction in murine islets using transcriptomic and immunolabeling approaches and in human pancreatic tissue using a publicly available transcriptomic dataset.<h4>Key findings</h4>Liraglutide similarly reduced glycemia in ad libitum-fed GHSR-null and control mice. Following food deprivation, liraglutide more effectively attenuated postprandial increases in glycemia in male, but not female, GHSR-null mice than in control mice. Liraglutide reduced glycemia in fasted GHSR-null male mice but not in WT males. In male mice, pretreatment with a LEAP2 (liver-expressed antimicrobial peptide 2) analog, an endogenous GHSR antagonist and inverse agonist, enhanced the glucose-lowering effects of liraglutide under postprandial and fasting conditions. GHSR and GLP-1R showed limited co-expression in murine islets. In human islets, their co-expression was also limited and enriched in δ-cells, but was also detected in β-cells, where the proportion of GHSR<sup>+</sup>/GLP-1R<sup>+</sup> cells was higher in donors with T2D.<h4>Significance</h4>GHSR inhibition enhances liraglutide's glucose-lowering effects in a sex-dependent manner, highlighting GHSR as a potential target to improve GLP-1R agonist efficacy.
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.